Facilitating Informed Decisions Regarding Microsatellite Instability Testing Among High-Risk Individuals Diagnosed With Colorectal Cancer
Sharon L. Manne(Fox Chase Cancer Center), Daniel C. Chung(Massachusetts General Hospital), Neal J. Meropol(Flatiron Health (United States)), David S. Weinberg(Fox Chase Cancer Center), Hetal S. Vig(Fox Chase Cancer Center), Cheri Manning(Fox Chase Cancer Center), Eric A. Ross(Fox Chase Cancer Center), Zohra Catts(Fox Chase Cancer Center), Kristen M. Shannon(Massachusetts General Hospital)
Cited by 47
Related Papers
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Quality Indicators for Colonoscopy
|The American Journal of Gastroenterology|2014|1.4k